Immunogenicity of viral vector, prime-boost SIV vaccine regimens in infant rhesus macaques: Attenuated vesicular stomatitis virus (VSV) and modified vaccinia Ankara (MVA) recombinant SIV vaccines compared to live-attenuated SIV

Vaccine

Volumn 28, Issue 6, 2010, Pages 1481-1492

  Van Rompay, Koen K A ^a   Abel, Kristina ^a,b   Earl, Patricia ^c   Kozlowski, Pamela A ^d   Easlick, Juliet ^a   Moore, Joseph ^a   Buonocore Buzzelli, Linda ^e   Schmidt, Kimberli A ^a   Wilson, Robert L ^d   Simon, Ian ^e   Moss, Bernard ^c   Rose, Nina ^e   Rose, John ^e   Marthas, Marta L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HIV; Oral; Pediatric; SIV; Vaccine

Indexed keywords

MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; UNCLASSIFIED DRUG; VESICULAR STOMATITIS VIRUS VACCINE; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG SAFETY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; VIRUS ENTRY;

ADMINISTRATION, ORAL; ANIMALS; ANIMALS, NEWBORN; GENETIC VECTORS; HIV ANTIBODIES; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; MACACA MULATTA; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VACCINATION; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VACCINIA VIRUS; VESICULOVIRUS;

EID: 75249102897     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.11.061     Document Type: Article

References (62)

1. John-Stewart G., Mbori-Ngacha D., Ekpini R., Janoff E.N., Nkengasong J., Read J.S., et al. Breast-feeding and transmission of HIV-1. J Acquir Immune Defic Syndr 35 2 (2004) 196-202
2. Jackson J.B., Musoke P., Fleming T., Guay L.A., Bagenda D., Allen M., et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 362 9387 (2003) 859-868
3. The Breastfeeding and HIV International Transmission Study (BHITS) Group. Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-analysis. J Infect Dis 189 (2004) 2154-2166
4. Kuhn L., Aldrovandi G.M., Sinkala M., Kankasa C., Semrau K., Mwiya M., et al. Effects of early, abrupt weaning on HIV-free survival of children in Zambia. N Engl J Med 359 2 (2008) 130-141
5. Shetty A.K., Coovadia H.M., Mirochnick M.M., Maldonado Y., Mofenson L.M., Eshleman S.H., et al. Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 months. J Acquired Immune Defic Syndr 34 5 (2003) 482-490
6. Safrit J.T., Ruprecht R., Ferrantelli F., Xu W., Kitabwalla M., Van Rompay K., et al. Immunoprophylaxis to prevent mother to child transmission of HIV-1. J Acquired Immune Defic Syndr 35 2 (2004) 169-177
7. Van Rompay KK. Evaluation of antiretrovirals in animal models of HIV infection. Antiviral Res, 2010.
8. Van Rompay K.K.A., Cherrington J.M., Marthas M.L., Berardi C.J., Mulato A.S., Spinner A., et al. 9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques. Antimicrob Agents Chemother 40 11 (1996) 2586-2591
9. Van Rompay K.K.A., McChesney M.B., Aguirre N.L., Schmidt K.A., Bischofberger N., and Marthas M.L. Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection. J Infect Dis 184 4 (2001) 429-438
10. Van Rompay K.K.A., Greenier J.L., Cole K.S., Earl P., Moss B., Steckbeck J.D., et al. Immunization of newborn rhesus macaques with simian immunodeficiency virus (SIV) vaccines prolongs survival after oral challenge with virulent SIVmac251. J Virol 77 (2003) 179-190
11. Abel K. The rhesus macaque pediatric SIV infection model - a valuable tool in understanding infant HIV-1 pathogenesis and for designing pediatric HIV-1 prevention strategies. Curr HIV Res 7 1 (2009) 2-11
12. Jaspan H.B., Lawn S.D., Safrit J.T., and Bekker L.G. The maturing immune system: implications for development and testing HIV-1 vaccines for children and adolescents. Aids 20 4 (2006) 483-494
13. Jaspan H.B., and Hanekom W.A. Immunology of infants through adolescents: responses to emulate for HIV vaccines. Curr Opin HIV AIDS 2 5 (2007) 391-398
14. Van Rompay K.K.A., Abel K., Lawson J.R., Singh R.P., Schmidt K.A., Evans T., et al. Attenuated poxvirus-based SIV vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV. J Acquired Immune Defic Syndr 38 2 (2005) 124-134
15. Abel K., Pahar B., Van Rompay K.K., Fritts L., Sin C., Schmidt K., et al. Rapid virus dissemination in infant macaques after oral simian immunodeficiency virus exposure in the presence of local innate immune responses. J Virol 80 13 (2006) 6357-6367
16. Clarke D.K., Cooper D., Egan M.A., Hendry R.M., Parks C.L., and Udem S.A. Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector. Springer Semin Immunopathol 28 3 (2006) 239-253
17. Egan M.A., Chong S.Y., Rose N.F., Megati S., Lopez K.J., Schadeck E.B., et al. Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes. AIDS Res Hum Retroviruses 20 9 (2004) 989-1004
18. Rose N.F., Marx P.A., Luckay A., Nixon D.F., Moretto W.J., Donahoe S.M., et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 106 5 (2001) 539-549
19. Ramsburg E., Rose N.F., Marx P.A., Mefford M., Nixon D.F., Moretto W.J., et al. Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol. J Virol 78 8 (2004) 3930-3940
20. Otsyula M.G., Miller C.J., Tarantal A.F., Marthas M.L., Greene T.P., Collins J.R., et al. Fetal or neonatal infection with attenuated simian immunodeficiency virus results in protective immunity against oral challenge with pathogenic SIVmac251. Virology 222 (1996) 275-278
21. Marthas M.L., Van Rompay K.K.A., Otsyula M., Miller C.J., Canfield D., Pedersen N.C., et al. Viral factors determine progression to AIDS in simian immunodeficiency virus-infected newborn rhesus macaques. J Virol 69 7 (1995) 4198-4205
22. Abel K., Compton L., Rourke T., Montefiori D., Lu D., Rothaeusler K., et al. Simian-human immunodeficiency virus SHIV89.6-induced protection against intravaginal challenge with pathogenic SIVmac239 is independent of the route of immunization and is associated with a combination of cytotoxic T-lymphocyte and alpha interferon responses. J Virol 77 5 (2003) 3099-3118
23. Johnson R.P., Lifson J.D., Czajak S.C., Cole K.S., Manson K.H., Glickman R., et al. Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. J Virol 73 6 (1999) 4952-4961
24. Lohman B.L., McChesney M.B., Miller C.J., McGowan E., Joye S.M., Van Rompay K.K.A., et al. A partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge. J Virol 68 11 (1994) 7021-7029
25. National Research Council. Guide for the care and use of laboratory animals (1996), National Academy Press, Washington, D.C.
26. Sackett G.P., Ruppenthal G.C., and Davis A.E. Survival, growth, health, and reproduction following nursery rearing compared with mother rearing in pigtailed monkeys (Macaca nemestrina). Am J Primatol 56 3 (2002) 165-183
27. Van Rompay K.K.A., Brignolo L.L., Meyer D.J., Jerome C., Tarara R., Spinner A., et al. Biological effects of short-term and prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA; tenofovir) to newborn and infant rhesus macaques. Antimicrob Agents Chemother 48 (2004) 1469-1487
28. Roberts A., Kretzschmar E., Perkins A.S., Forman J., Price R., Buonocore L., et al. Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. J Virol 72 6 (1998) 4704-4711
29. Earl P.L., Wyatt L.S., Montefiori D.C., Bilska M., Woodward R., Markham P.D., et al. Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric env protein boost in the SHIV rhesus macaque model. Virology 294 (2002) 270-281
30. Zhu Y., Rota P., Wyatt L., Tamin A., Rozenblatt S., Lerche N., et al. Evaluation of recombinant vaccinia virus-measles vaccines in infant rhesus macaques with preexisting measles antibody. Virology 276 (2000) 202-213
31. Van Rompay K.K., Johnson J.A., Blackwood E.J., Singh R.P., Lipscomb J., Matthews T.B., et al. Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection. Retrovirology 4 1 (2007) 25
32. Kozlowski P.A., Lynch R.M., Patterson R.R., Cu-Uvin S., Flanigan T.P., and Neutra M.R. Modified wick method using Weck-Cel sponges for collection of human rectal secretions and analysis of mucosal HIV antibody. J Acquir Immune Defic Syndr 24 4 (2000) 297-309
33. Shacklett B.L., Cox C.A., Sandberg J.K., Stollman N.H., Jacobson M.A., and Nixon D.F. Trafficking of human immunodeficiency virus type 1-specific CD8+ T cells to gut-associated lymphoid tissue during chronic infection. J Virol 77 10 (2003) 5621-5631
34. Van Rompay K.K.A., Singh R.P., Pahar B., Sodora D.L., Wingfield C., Lawson J.R., et al. CD8+ cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment. J Virol 78 (2004) 5324-5337
35. Simon I.D., Publicover J., and Rose J.K. Replication and propagation of attenuated vesicular stomatitis virus vectors in vivo: vector spread correlates with induction of immune responses and persistence of genomic RNA. J Virol 81 4 (2007) 2078-2082
36. Manrique M., Kozlowski P.A., Wang S.-W., Wilson R.L., Micewicz E., Montefiori D.C., et al. Nasal DNA-MVA SIV vaccination provides more significant protection from progression to AIDS than a similar intramuscular vaccination. Mucosal Immunol 2 6 (2009) 536-550
37. Wang S.W., Kozlowski P.A., Schmelz G., Manson K., Wyand M.S., Glickman R., et al. Effective induction of simian immunodeficiency virus-specific systemic and mucosal immune responses in primates by vaccination with proviral DNA producing intact but noninfectious virions. J Virol 74 22 (2000) 10514-10522
38. Van Rompay K.K.A., Marthas M.L., Lifson J.D., Berardi C.J., Vasquez G.M., Agatep E., et al. Administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques. AIDS Res Hum Retroviruses 14 9 (1998) 761-773
39. Pahar B., Li J., Rourke T., Miller C.J., and McChesney M.B. Detection of antigen-specific T cell interferon-γ expression by ELISPOT and cytokine flow cytometry assays in rhesus macaques. J Immunol Methods 282 (2003) 103-115
40. Miller C.J., Marthas M., Greenier J., Lu D., Dailey P., and Lu Y. In vivo replication capacity rather than in vitro macrophage tropism predicts efficiency of vaginal transmission of simian immunodeficiency virus or simian/human immunodeficiency virus in rhesus macaques. J Virol 72 4 (1998) 3248-3258
41. Van Rompay K.K., Blackwood E.J., Landucci G., Forthal D., and Marthas M.L. Role of CD8+ Cells in controlling replication of nonpathogenic simian immunodeficiency virus SIVmac1A11. Virol J 3 1 (2006) 22
42. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., et al. Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand. N Engl J Med 361 (2009) 2209-2220
43. Van Rompay K.K.A., Dailey P.J., Tarara R.P., Canfield D.R., Aguirre N.L., Cherrington J.M., et al. Early short-term 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) treatment favorably alters subsequent disease course in simian immunodeficiency virus-infected newborn rhesus macaques. J Virol 73 4 (1999) 2947-2955
44. Van Rompay K.K.A., Singh R.P., Heneine W., Johnson J.A., Montefiori D.C., Bischofberger N., et al. Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaques. J Virol 80 13 (2006) 6399-6410
45. Abel K., La Franco-Scheuch L., Rourke T., Ma Z.M., De Silva V., Fallert B., et al. Gamma interferon-mediated inflammation is associated with lack of protection from intravaginal simian immunodeficiency virus SIVmac239 challenge in simian-human immunodeficiency virus 89.6-immunized rhesus macaques. J Virol 78 2 (2004) 841-854
46. Marthas M.L., Sutjipto S., Higgins J., Lohman B., Torten J., Luciw P.A., et al. Immunization with a live, attenuated simian immunodeficiency virus (SIV) prevents early disease but not infection in rhesus macaques challenged with pathogenic SIV. J Virol 64 8 (1990) 3694-3700
47. Marthas M.L., Miller C.J., Sutjipto S., Higgins J., Torten J., Lohman B.L., Unger R.E., Ramos R.A., Kiyono H., McGhee J.R., Marx P.A., and Pedersen N.C. Efficacy of live-attenuated and whole-inactivated simian immunodeficiency virus vaccines against vaginal challenge with virulent SIV. J Med Primatol 21 (1992) 99-107
48. Marthas M.L., Ramos R.A., Lohman B.L., Van Rompay K.K.A., Unger R.E., Miller C.J., et al. Viral determinants of simian immunodeficiency virus (SIV) virulence in rhesus macaques assessed by using attenuated and pathogenic molecular clones of SIVmac. J Virol 67 10 (1993) 6047-6055
49. Hirsch V.M., Fuerst T.R., Sutter G., Carroll M.W., Yang L.C., Goldstein S., et al. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J Virol 70 6 (1996) 3741-3752
50. Seth A., Ourmanov I., Schmitz J.E., Kuroda M.J., Lifton M.A., Nickerson C.E., et al. Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) gag-pol primes for an anamnestic gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge. J Virol 74 (2000) 2502-2509
51. Shiver J.W., Fu T.-M., Chen L., Casimiro D.R., Davies M.-E., Evans R.K., et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency virus immunity. Nature 415 (2002) 331-335
52. Robinson H.L., and Amara R.R. T cell vaccines for microbial infections. Nat Med 11 4 Suppl. (2005) S25-32
53. Egan M.A., Chong S.Y., Megati S., Montefiori D.C., Rose N.F., Boyer J.D., et al. Priming with plasmid DNAs expressing interleukin-12 and simian immunodeficiency virus gag enhances the immunogenicity and efficacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus. AIDS Res Hum Retroviruses 21 7 (2005) 629-643
54. Zhang J.Y., Martin L.N., Watson E.A., Montelaro R.C., West M., Epstein L., et al. Simian immunodeficiency virus/delta-induced immunodeficiency disease in rhesus monkeys: relation of antibody response and antigenemia. J Infect Dis 158 6 (1988) 1277-1286
55. Hogervorst E., Jurriaans S., de Wolf F., van Wijk A., Wiersma A., Valk M., et al. Predictors for non- and slow progression in human immunodeficiency virus (HIV) type 1 infection: low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels. J Infect Dis 171 4 (1995) 811-821
56. Cheingsong-Popov R., Panagiotidi C., Bowcock S., Aronstam A., Wadsworth J., and Weber J. Relation between humoral responses to HIV gag and env proteins at seroconversion and clinical outcome of HIV infection. Br Med J 302 6767 (1991) 23-26
57. Binley J.M., Klasse P.J., Cao Y., Jones I., Markowitz M., Ho D.D., et al. Differential regulation of the antibody response to gag and env proteins of human immunodeficiency virus type 1. J Virol 71 4 (1997) 2799-2809
58. Ferrantelli F., Rasmussen R.A., Buckley K.A., Li P.L., Wang T., Montefiori D.C., et al. Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. J Infect Dis 189 12 (2004) 2167-2173
59. Greenier J.L., Van Rompay K.K.A., Montefiori D., Earl P., Moss B., and Marthas M.L. Simian immunodeficiency virus (SIV) envelope quasispecies transmission and evolution in infant rhesus macaques after oral challenge with uncloned SIVmac251: increased diversity is associated with neutralizing antibodies and improved survival in previously immunized animals. Virol J 2 (2005) 11
60. Forthal D.N., Landucci G., Cole K.S., Marthas M., Becerra J.C., and Van Rompay K. Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells. J Virol 80 18 (2006) 9217-9225
61. Florese R.H., Van Rompay K.K., Aldrich K., Forthal D.N., Landucci G., Mahalanabis M., et al. Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challenge. J Immunol 177 6 (2006) 4028-4036
62. Van Rompay K.K.A., Berardi C.J., Dillard-Telm S., Tarara R.P., Canfield D.R., Valverde C.R., et al. Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection. J Infect Dis 177 5 (1998) 1247-1259